首页|2型糖尿病患者对口服降糖药治疗偏好的定性研究:以北京市患者为例

2型糖尿病患者对口服降糖药治疗偏好的定性研究:以北京市患者为例

扫码查看
目的 探讨我国2型糖尿病患者对口服降糖药物的治疗偏好.方法 在北京市3所不同级别医院招募并访谈2型糖尿病患者.基于半结构式访谈提纲收集患者在选择口服药物时会考虑的因素.将访谈录音转录为文本,采用扎根理论的相关技术从文本中提取重要信息进行编码,将提取出的编码进行归纳、分类并形成主题.结果 研究共纳入27例患者,基于定性数据分析,共归纳出5个主题,分别为疗效的关注、服药风险的规避、用药负担的考量、用药成本的考量以及可信赖药物的青睐.结论 2型糖尿病患者在评价和选择口服降糖药物时会从多个方面进行考虑.医疗卫生服务的提供者应关注2型糖尿病患者的用药偏好,从而制定以患者为中心的治疗计划,以实现最佳的临床结果和患者依从性,并最终改善患者的健康状况.
A qualitative study of oral antidiabetic medication treatment preference for type 2 diabetes patients:a case study of patients in Beijing
Objective To explore the treatment preferences of oral antidiabetic medications in Chinese type 2 diabetes patients.Methods Patients with type 2 diabetes were recruited and interviewed in three hospitals of different levels in Beijing.Semi-structured interviews were conducted to collect the factors that patients would consider when choosing oral antidiabetic medications.The interviews were recorded and transcribed into texts.Techniques of grounded theory were used to code important information from the texts.The extracted codes were summarized,classified and generated themes.Results A total of 27 patients were included in the study.Based on qualitative data analysis,five themes were summarized,namely,attention to efficacy,avoidance of medication risks,consideration of medication burden,consideration of medication costs,and the favor of reliable medication.Conclusions Patients with type 2 diabetes consider multiple aspects when evaluating and choosing oral antidiabetic medications.Healthcare services providers should focus on the medication preferences of people with type 2 diabetes to develop patient-centered treatment plans to achieve optimal adherence and clinical outcomes,and ultimately improve their health and well-being.

type 2 diabetesoral antidiabetic medicationpatient preferenceadherencequalitative research

毛竹欣、庄铃香、谢诗桐、吴晶

展开 >

比利时安特卫普大学健康经济与传染病建模研究中心,安特卫普2610

瑞典于默奥大学流行病学和全球健康学院,于默奥90187

天津大学药物科学与技术学院,天津 300072

天津大学社会科学调查与数据中心,天津 300072

展开 >

2型糖尿病 口服降糖药 患者偏好 依从性 定性研究

国家自然科学基金

71673197

2024

世界临床药物
上海医药工业研究院

世界临床药物

CSTPCD
影响因子:0.849
ISSN:1672-9188
年,卷(期):2024.45(1)
  • 24